Novel data on opioid effect on breathing and analgesia

Seminars in Anesthesia, Perioperative Medicine and Pain

Volumn 26, Issue 2, 2007, Pages 58-64

  Dahan, Albert ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Genetic polymorphism; Naloxone; Pain; Respiratory depression; Sex differences; Take home naloxone

Indexed keywords

ALFENTANIL; ANALGESIC AGENT; BUPRENORPHINE; DOXAPRAM; FENTANYL; MORPHINE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; NALOXONE; OPIATE; OPIATE ANTAGONIST; SEROTONIN RECEPTOR;

ANALGESIA; ARTICLE; BREATHING; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG OVERDOSE; GENE; GENE FREQUENCY; HUMAN; MUTATION; NAUSEA; NONHUMAN; OPIATE ADDICTION; OPRM GENE; OPRM1 GENE; PRIORITY JOURNAL; RESPIRATION CONTROL; RESPIRATION DEPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; VOMITING;

EID: 34548226909     PISSN: 02770326     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.sane.2007.04.003     Document Type: Article

References (69)

1. Bovill J.G. Opium: a drug ancient and modern. In: Dahan A., and van Kleef J.W. (Eds). Advances in Anesthesia and Analgesia: 22 Years of Research in Anesthesiology at Leiden University and LUMC (2007), Department of Anesthesiology (LUMC), Leiden 13-27
2. Sertürner F. UÜber das Morphium, eine neue salzfähige Grundlage, und die Mekonsäure, als Hauptbestandtheile des Opiums. Annalen der Physik 5 (1817) 56-75
3. Zubieta J.K., Smith Y.R., Bueller J.A., et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 393 (2001) 311-315
4. Inoue M., Kobayashi M., Kozaki S., et al. Nociceptin/orphanin FQ-induced nociceptive responses through substance P release from peripheral nerve endings in mice. Proc Natl Acad Sci USA 95 (1998) 10949-10953
5. Berkenbosch A., Teppema L.J., Olievier C.N., et al. Influences of morphine on the ventilatory response to isocapnic hypoxia. Anesthesiology 86 (1997) 1342-1349
6. Gray P.A., Reckling J.C., Bocchiaro C.M., et al. Modulation of respiratory frequency by peptidergic inupt to rhythmogenic neurons in the preBötzinger complex. Science 286 (1999) 1566-1568
7. Bailey P.L., Lu J.K., Pace N.L., et al. Effects of intrathecal morphine on the ventilatory response to hypoxia. N Engl J Med 343 (2000) 12228-12234
8. Dahan A., Romberg R., Teppema L., et al. Simultaneous measurement and integrated analysis of analgesia and respiration after an intravenous morphine infusion. Anesthesiology 101 (2004) 1201-1209
9. Cashman J.N., and Dolin S.J. Respiratory and haemodynamic effects of acute postoperative pain management: evidence from published data. Br J Anaesth 93 (2004) 212-223
10. Taylor S., Kirton O.C., Staff I., et al. Postoperative day one: a high risk period for respiratory depression. Am J Surg 190 (2005) 752-756
11. Overdyk F., Maddox R., and Carter R. Incidence of respiratory depression with PCA using continuous oximetry and capnography monitoring (abstract). Anesthesiology 105 (2006) A133
12. Lötsch J., Dudziak R., Freynhagen R., et al. Fatal respiratory depression after multiple intravenous morphine injection. Clin Pharmacokinet 45 (2006) 1051-1060
13. Dahan A., and Teppema L. Influence of anaesthesia and analgesia on the control of breathing. Br J Anaesth 91 (2003) 40-49
14. Dahan A., DeGoede J., Berkenbosch A., et al. The influence of oxygen on the ventilatory response to carbon dioxide in man. J Physiol (London) 428 (1990) 485-499
15. Sarton E., Dahan A., Teppema L., et al. Influence of acute pain induced by activation of cutaneous nociceptors on ventilatory control. Anesthesiology 87 (1997) 289-296
16. Karan S., Voter W., Palmer L., et al. Effects of pain and audiovisual stimulation on the opioid-induced depression of the hypoxic ventilatory response. Anesthesiology 103 (2005) 384-390
17. Dahan A., Yassen A., Romberg R., et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 96 (2006) 627-632
18. Pan Y.X., Bolan E., Moskowitz H.S., et al. Identification of four novel exon 5 splice variants of the mouse μ-opioid receptor gene: functional consequences of C-terminal splicing. Mol Pharmacol 68 (2005) 866-875
19. Kieffer B.L. Opioids: first lessons from knockout mice. TIPS 20 (1999) 19-26
20. Matthes H.W.D., Maldonado R., Simonin F., et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid receptor gene. Nature 383 (1996) 819-823
21. Sora I., Takahashi N., Funada M., et al. Opiate receptor knockout mice define μ receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 94 (1997) 1544-1549
22. Loh H.H., Liu H.C., Cavelli A., et al. μ-Opioid receptor knockout mice: effects on ligand-induced analgesia and morphine lethality. Mol Brain Res 54 (1998) 321-326
23. Schuller A.G.P., King M.A., Zhang J., et al. Retention of heroin and morphine-6β-glucuronide analgesia in a new line of mice lacking exon 1 of MOR1. Nat Neurosci 2 (1999) 151-156
24. Matthes H.W.D., Smadja C., Valverde O., et al. Activity of the δ-opioid receptor is partially reduced, whereas activity of the κ-receptor is maintained in mice lacking the μ-receptor. J Neurosci 18 (1998) 7285-7295
25. Dahan A., Sarton E., Teppema L., et al. Anesthetic potency and influence of morphine and sevoflurane on respiration in μ-opioid receptor knockout mice. Anesthesiology 94 (2001) 824-832
26. Romberg R., Sarton E., Teppema L., et al. No difference between morphine and morphine-6-glucuronide on respiration in μ-opioid receptor-deficient mice. Br J Anaesth 91 (2003) 862-870
27. Landau R., Cahana A., Smiley R.M., et al. Genetic variability of μ-opioid receptor in an obstetric population. Anesthesiology 100 (2004) 1030-1033
28. Bond C., LaForge K.S., Tian M., et al. Single nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95 (1998) 9608-9613
29. 118G polymorphism and substance dependence. Am J Med Gen 105 (2001) 114-119
30. Comptom P., Geschwind D.H., and Alarcón M. Association between human μ-opioid receptor gene polymorphism, pain tolerance and opioid addiction. Am J Med Gen (Part B) 121B (2003) 76-82
31. Hernandez-Avila C.A., Wand G., Luo X., et al. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the μ-opioid receptor locus (Oprm1). Am J Med Gen (Part B) 118B (2003) 60-65
32. Lötsch J., Skarke C., Grösch S., et al. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12 (2002) 3-9
33. Skarke C., Darimont J., Schmidt H., et al. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous pain model in healthy volunteers. Clin Pharmacol Ther 73 (2003) 107-121
34. Klepstad P., Rakvåg T.T., Kaasa S., et al. The 118A>G polymorphism in the human μ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 48 (2004) 1232-1239
35. Romberg R., Olofsen E., Sarton E., et al. Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide induced analgesia in healthy volunteers: absence of sex differences. Anesthesiology 100 (2004) 120-133
36. Romberg R.R., Olofsen E., Bijl H., et al. Polymorphism of the μ-opioid receptor gene (OPRM1:c. 118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 102 (2005) 522-530
37. Oertel B.G., Schmidt R., Schneider A., et al. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 16 (2006) 626-636
38. Reyes-Gibby C.C., Shete S., Rakvag T., et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130 (2007) 25-30
39. Rakvag T.T., Klepstad P., Baar C., et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116 (2005) 73-78
40. Mogil J., Ritchie J., Smith S.B., et al. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet 42 (2005) 583-587
41. Park H.J., Shinn H.K., Ryu S.H., et al. Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther 81 (2007) 5390-5394
42. Dahan A., Sarton E., Teppema L., et al. Sex-related differences in influence of morphine on ventilatory control in humans. Anesthesiology 88 (1998) 903-913
43. Sarton E., Dahan A., and Teppema L. Sex differences in morphine-induced ventilatory depression resides within the peripheral chemoreflex loop. Anesthesiology 90 (1999) 1329-1338
44. Sarton E., Olofsen E., Romberg R., et al. Sex differences in morphine analgesia: An experimental study in healthy volunteers. Anesthesiology 93 (2000) 1245-1254
45. Gross J.B. When you breathe IN you inspire, when you DON′T breathe, you ... ... expire: new insights regarding opioid-induced respiratory depression (editorial). Anesthesiology 99 (2003) 767-770
46. Dahan A., Yassen M., Bijl H., et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 94 (2005) 825-834
47. van Dorp E.L.A., Romberg R., Sarton E., et al. Morphine-6-glucuronide: morphine's successor for postoperative pain relief?. Anesth Anal 102 (2006) 1789-1797
48. Romberg R., Olofsen E., Sarton E., et al. Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. Anesthesiology 99 (2003) 788-798
49. Budd K., and Collett J.B. Buprenorphine: old dog - new (ma)trix. Br J Anaesth 90 (2003) 724-744
50. van Dorp E., Yassen A., and Dahan A. Naloxone treatment in opioid addiction: the risks and benefits. Expert Opinion Drug Safety 6 (2007) 125-132
51. Yassen A., and Danhof M. Mechanism-based PK-PD modeling of opioid analgesics. In: Dahan A., and van Kleef J.W. (Eds). Advances in Anesthesia and Analgesia: 22 Years of Research in Anesthesiology at Leiden University and LUMC (2007), Department of Anesthesiology (LUMC), Leiden 115-122
52. Moro C., Taino R., Mandala M., et al. Buprenorphine-induced acute respiratory depression during ifosfamide-based chemotherapy. Ann Oncol 17 (2006) 1466-1467
53. Geib A.J., Babu K., Ewald M.B., et al. Adverse effects in children after unintentional buprenorphine exposure. Pediatrics 118 (2006) 1746-1751
54. Reynaud M., Tracqui A., Petit G., et al. Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. Am J Psychiatry 155 (1998) 448-449
55. van Dorp E., Yassen A., Sarton E., et al. Naloxone reversal reversal of buprenorphine-induced respiratory depression. Anesthesiology 105 (2006) 51-57
56. Flacke J.W., Flacke W.E., and Williams G.D. Acute pulmonary edema following naloxone reversal of high-dose morphine anesthesia. Anesthesiology 47 (1977) 376-378
57. Kagawa S., Stafford M.J., Waggener T.B., et al. No effect of naloxone on hypoxia-induced ventilatory depression in adults. J Appl Physiol 52 (1982) 1030-1034
58. Gall T.J. Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol Ther 45 (1989) 66-71
59. Dettmer K., Saunders B., and Strang J. Take home naloxone and the prevention of fatal heroin overdose: two pilot schemes. BMJ 322 (2001) 895-896
60. Galea S., Worthington N., Markham P.T., et al. Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in NYC. Addict Behav 31 (2006) 907-912
61. Takahashi M., Sugiyama K., Hori M., et al. Naloxone reversal of opioid anesthesia: clinical evaluation and plasma concentrations of continuous naloxone infusion after anesthesia with high-dose fentanyl. J Anesth 18 (2004) 1-8
62. Cotten J.F., Keshavaprasad B., Laster M.J., et al. The ventilatory stimulant doxapram inhibits TASK tandem pore (K2P) potassium channel function but does not affect minimum alveolar anesthetic concentration. Anesth Analg 102 (2006) 779-785
63. 4(a) receptors avert opioid-induced breathing depression without loss of analgesia. Science 301 (2003) 226-229
64. Lötsch J., Skarke C., Schneider A., et al. The 5-hydroxytryptamine 4 receptor agonist mosapride does not antagonize morphine-induced respiratory depression. Clin Pharmacol Ther 78 (2005) 278-287
65. 1A receptor agonist Buspirone does not antagonize morphine-induced respiratory depression. Clin Pharmacol Ther 81 (2007) 59-68
66. Faculty of 1000 Medicine, 20 Nov 2006. Available at. http://www.f1000medicine.com/ article/id/1046346/evaluation
67. Brown K.A., Laferrière A., and Ravé Moss I. Recurrent hypoxemia in young children with obstructive sleep apnea is associated with reduced opioid requirements for analgesia. Anesthesiology 100 (2004) 806-810
68. Brown K.A., Laferrière A., Lakheeram I., et al. recurrent hypoxemia in children is associated with increased analgesic sensitivity to opiates. Anesthesiology 105 (2006) 665-669
69. Ravé Moss I., Brown K.A., and Laferrière A. Recurrent hypoxia in rats during development increases subsequent respiratory sensitivity to fentanyl. Anesthesiology 105 (2006) 715-718